Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa

Domaine:

healthcare

Type de record:

paper

Créateur:

ZubEliFreFab

Éditeur:

Ame

Hôte:

Rifampin monoresistance (RMR; rifampin resistance and isoniazid susceptibility) accounts for 38% of all rifampin-resistant tuberculosis (RR-TB) in South Africa and is increasing. We aimed to compare RMR-TB with multidrug-resistant TB (MDR-TB) in a setting with high TB, RR-TB, and HIV burdens.

Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa

Substance use (SU) is associated with poor rifampicin-resistant tuberculosis (RR-TB) treatment outco

Therapeutic threshold for rifampicin-resistant tuberculosis: a case report from Maputo, Mozambique

Objectives Frequently used rapid rifampicin drug susceptibility tests (RMP-DST) miss certain rifampi

Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis

Objectives South Africa ranks among the highest drug-re

Low Detection Rate of Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in the Democratic Republic of Congo: Trend Analysis 2013-2017

Prevalence of rifampicin resistant tuberculosis among pulmonary tuberculosis patients In Enugu, Nigeria

Objective: We determined the prevalence of rifampicin resistance in pulmonary tuberculosis patients

Rifampicin resistance patterns and dynamics of tuberculosis and drug-resistant tuberculosis in Enugu, South Eastern Nigeria

Introduction: Tuberculosis (TB) continues to be a public health problem globally. The burden is furt